- 2024-08-20 01:54抑制剂DS-7423|DS-7423|1222104-37-1|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 01:54抑制剂DS-7423|DS-7423|1222104-37-1|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:54抑制剂DS-7423|DS-7423|1222104-37-1|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:54抑制剂DPH|DPH|484049-04-9|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:54抑制剂DS-6051b|Taletrectinib|1505515-69-4|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 01:54抑制剂DS-6051b|Taletrectinib|1505515-69-4|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:53抑制剂DPH|DPH|484049-04-9|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:53抑制剂DPH|DPH|484049-04-9|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 01:53抑制剂Dp44mT|Dp44mT|152095-12-0|Adamas life|≥98%（以实测数值为准）|BR|500mg
- 2024-08-20 01:53抑制剂DOTA-tris(tBu)ester NHS ester|DOTA-tris(tBu)ester NHS ester|819869-77-7|Adamas life|≥98%（以实测数值为准）
- 2024-08-20 01:53抑制剂Dp44mT|Dp44mT|152095-12-0|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 01:53抑制剂Dp44mT|Dp44mT|152095-12-0|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:53抑制剂Dot1L-IN-4|Dot1L-IN-4|2565705-02-2|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:53抑制剂DOTA-tris(tBu)ester NHS ester|DOTA-tris(tBu)ester NHS ester|819869-77-7|Adamas life|≥98%（以实测数值为准）
- 2024-08-20 01:53抑制剂DOTA-tris(tBu)ester NHS ester|DOTA-tris(tBu)ester NHS ester|819869-77-7|Adamas life|≥98%（以实测数值为准）
- 2024-08-20 01:53抑制剂Dopamine D2 receptor agonist-2|Dopamine D2 receptor agonist-2|1610591-93-9|Adamas life|≥98%（以实测数值
- 2024-08-20 01:53抑制剂Dopamine D2 receptor agonist-2|Dopamine D2 receptor agonist-2|1610591-93-9|Adamas life|≥98%（以实测数值
- 2024-08-20 01:53抑制剂Dopamine D2 receptor agonist-2|Dopamine D2 receptor agonist-2|1610591-93-9|Adamas life|≥98%（以实测数值
- 2024-08-20 01:53抑制剂DODMA|DODMA|104162-47-2|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:53抑制剂Dooku1|Dooku1|2253744-54-4|Adamas life|≥98%（以实测数值为准）|BR|100mg
